Source: International Congress 2016 – The future of tyrosin kinase inhibitors



Rating:

Share or cite this content

Citations should be made in the following way:
Martin Kolb (Hamilton, Canada). Re-purposing TKI treatment. International Congress 2016 – The future of tyrosin kinase inhibitors

Member's Comments

No comment yet.

Related content which might interest you: EGFR TKI in the current clinical practice Source: ERS Research Seminar Year: 2015 The response to erlotinib third-line treatment in bronchioalveolar carcinoma in the absence of EGFR expression Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Failure of EGFR TKI treatment: mechanisms and current strategies? Source: ERS Research Seminar Year: 2015 Metformin improves survival in lung cancer patients receiving EGFR-TKIs therapy> Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018 Erlotinib as salvage treatment after failure to gefitinib in non-small cell lung cancer Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Maintenance treatment with erlotinib after induction chemotherapy for advanced NSCLC Source: Annual Congress 2011 - Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer Year: 2011 Pulmonary hypertension in patients treated with Src/Abl kinase inhibitor dasatinib Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Gefitinib (‘Iressa’, ZD1839) improves disease-related symptoms in NSCLC Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003 Targeting STAT3 pathway signalling in EGFR TKI resistant NSCLC Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers Year: 2020 Dynamic monitoring of EGFR mutations in circulating tumor DNA for early detection of drug resistance in NSCLC patients on EGFR-TKI therapy Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer Year: 2019 EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice Source: Eur Respir J, 50 (2) 1700514; 10.1183/13993003.00514-2017 Year: 2017 The future generations of TKIs Source: International Congress 2016 – The future of tyrosin kinase inhibitors Year: 2016 Cost-effectiveness of afatinib versus erlotinib for the treatment of squamous non-small cell lung cancer in france after a first-line platinum based therapy Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Short-term efficacy of advanced NSCLC patients receiving anlotinib hydrochloride as the first and second-line treatment Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Mutations of EGFR and k-ras genes and TK inhibitors. Are there differences between gefitinib and erlotinib? Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Phase I trial of pemetrexed, carboplatin and sorafenib as first-line treatment in patients with metastatic NSCLC Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010